Acute Myeloid Leukemia (AML) – Drug Pipeline Analysis and Market Forecasts to 2016

The AML Therapeutics Market is Forecast to Show Increased Growth Until 2016

Online PR News – 06-January-2010 – – GlobalData has estimated the global AML therapeutics market to be valued at $174m in 2009. It is expected to grow to $329m with a Compound Annual Growth Rate (CAGR) of 9.5% by 2016. This growth is primarily attributed to the increase in competition among the existing products and also the strong pipeline with more emerging therapies. Pfizer and Genzyme remain the market leaders within the global AML Therapeutics market. Globally, the US remains the largest market for AML therapeutics, and was valued at $104m in 2009, and is forecast to grow at a CAGR of 9.5% over the next seven years to reach $198m by 2016. However, with most of the demand coming from the developed economies, the global AML therapeutics market activity is potentially due for a paradigm shift.

For further details please click or add the below link to your browser:

The pipeline assessment shows that the AML therapeutics pipeline is strong. There are 22 molecules in Phase III making up 10% of the AML therapeutics pipeline. Phase II pipeline comprises of 115 molecules which forms 52% of the total AML therapeutics pipeline. Phase I contains 75 molecules (34%), preclinical comprises of 5 molecules forming 2% of the pipeline. Overall, pipeline assessment suggests that the pipeline for the AML therapeutics market is strong and there are certain novel molecules that are likely to offer better safety.

The AML therapeutics market has unmet needs in terms of both, efficacy and safety. These unmet needs imply that the market is moderately served by the current product options, and has a wide scope available for new entrants to capture value from the underserved segments. The efficacy of current product offerings in the AML therapeutics market is substantially moderate.

For further details please click or add the below link to your browser:

All the therapeutics have more or less, low safety profiles. The annual cost of therapy for branded products ranges from $2050 to $8000. These prices are relatively high when compared to other diseases. A new product with superior results than the existing products may be sold at a higher cost. For new products that retain the same efficacy and safety, pricing would be one potential leverage point.

GlobalData, the industry analysis specialist, has released its latest research “Acute Myeloid Leukemia (AML) - Drug Pipeline Analysis and Market Forecasts to 2016”. It provides key data, information and analysis on the global AML therapeutics market. The report provides a comprehensive overview of annualized market data from 2001 to 2009, and forecasts for the next seven years to 2016. The report covers the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is analyzed along with the prevailing unmet need or commercial opportunities of the market. The pipeline analysis covers molecules across all phases of clinical development and gives an overview of the developing trends among pipeline molecules, as well as, an insight into the most promising pipeline drugs, supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for future market competition is also outlined.

For further details please click or add the below link to your browser:

Or Visit our report store: